Baltimore, MD, United States of America

Tracy Perry


Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 70(Granted Patents)


Company Filing History:


Years Active: 2009-2021

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Tracy Perry: Innovator in Diabetes Treatment

Introduction

Tracy Perry is a notable inventor based in Baltimore, MD (US), recognized for his contributions to the field of diabetes treatment. With a total of 4 patents, Perry has made significant strides in developing innovative polypeptide analogs that have the potential to improve the lives of individuals with diabetes.

Latest Patents

Perry's latest patents focus on GLP-1, exendin-4, and their peptide analogs. These inventions relate to novel polypeptide analogs that are insulinotropic and long-acting. In a preferred embodiment, the polypeptide's insulinotropic effect is comparable to or exceeds that of an equimolar amount of GLP-1 or exendin-4. The invention also encompasses methods for treating subjects with diabetes by administering the polypeptide in an amount that has an insulinotropic effect. Additionally, it includes methods for utilizing GLP-1, exendin-4, and their polypeptide analogs for neuroprotective and neurotrophic effects.

Career Highlights

Tracy Perry is currently affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this prestigious institution has allowed him to focus on groundbreaking research that addresses critical health issues.

Collaborations

Perry has collaborated with esteemed colleagues, including Nigel H. Greig and Josephine M. Egan, who have contributed to his research endeavors.

Conclusion

Tracy Perry's innovative work in developing polypeptide analogs for diabetes treatment showcases his commitment to advancing medical science. His contributions have the potential to significantly impact the management of diabetes and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…